ArticleIndian journal of endocrinology and metabolism
Serum Cell-Free DNA as Predictor of Progression of Kidney Disease in Diabetes: A Single-Center Prospective Study.
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease with significant variability in progression among individuals. Identifying reliable biomarkers to predict DKD progression remains a critical unmet need. This study aimed to evaluate the role of cell-free DNA (cfDNA) as a biomarker for predicting the progression of DKD in patients with type 2 diabetes mellitus (T2DM). Methods: In this prospective study, T2DM patients aged 18-80 years with DKD (estimated glomerular filtration rate [eGFR] 20-60 ml/min/1.73 m² and/or urinary albumin-to-creatinine ratio (UACR) 30-300 mg/gm) were recruited and were followed every 6 months for 18 months. Progression was defined as a ≥20% decline in eGFR and/or UACR > 300 mg/gm. Baseline cfDNA was retrospectively analyzed for progression of DKD. Multiple logistic regression analysis was performed to explore the association between cfDNA and the progression of DKD by adjusting in different models. Results: Out of 154 T2DM patients with DKD, 140 participants completed the study and progression was found to be in 63 (45%) of patients. Median baseline cfDNA levels were significantly higher in the progressive group than in the nonprogressive group (197.23 ng/ml vs. 138.79 ng/ml, Conclusion: cfDNA independently predicts DKD progression in T2DM patients. However, future large-scale, long-term studies are necessary to validate these findings for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.